Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	double-stranded telomeric DNA binding	ZBTB48 RAD50	1.26e-04	9	38	2	GO:0003691
GeneOntologyMolecularFunction	cytoskeletal protein binding	KIFAP3 AFDN MYH7 CALML4 DNAL1 MTUS1 CENPE FARP1 CEP290	1.72e-04	1099	38	9	GO:0008092
GeneOntologyBiologicalProcess	organelle assembly	RNF213 MYH7 SPG11 DNAL1 RPGRIP1L RB1CC1 CENPE AP3D1 CEP290 RTTN SSX2IP CEP63	5.34e-07	1138	38	12	GO:0070925
GeneOntologyBiologicalProcess	synaptic vesicle localization	SPG11 FGFR2 AP3D1 PCLO	8.71e-06	71	38	4	GO:0097479
GeneOntologyBiologicalProcess	microtubule-based process	KIFAP3 TACR2 SPG11 DNAL1 CENPE AP3D1 CEP290 RTTN SSX2IP CEP63	1.53e-05	1058	38	10	GO:0007017
GeneOntologyBiologicalProcess	organelle localization	KIFAP3 SPG11 FGFR2 CENPE AP3D1 PCLO CEP290 CEP63	3.46e-05	703	38	8	GO:0051640
GeneOntologyBiologicalProcess	establishment of vesicle localization	KIFAP3 SPG11 FGFR2 AP3D1 PCLO	5.41e-05	224	38	5	GO:0051650
GeneOntologyBiologicalProcess	establishment of organelle localization	KIFAP3 SPG11 FGFR2 CENPE AP3D1 PCLO CEP63	5.42e-05	546	38	7	GO:0051656
GeneOntologyBiologicalProcess	vesicle localization	KIFAP3 SPG11 FGFR2 AP3D1 PCLO	8.60e-05	247	38	5	GO:0051648
GeneOntologyBiologicalProcess	otic vesicle formation	FGFR2 CEP290	1.18e-04	9	38	2	GO:0030916
GeneOntologyBiologicalProcess	synaptic vesicle transport	SPG11 FGFR2 AP3D1	1.34e-04	54	38	3	GO:0048489
GeneOntologyBiologicalProcess	otic vesicle morphogenesis	FGFR2 CEP290	2.16e-04	12	38	2	GO:0071600
GeneOntologyBiologicalProcess	cilium organization	KIFAP3 DNAL1 RPGRIP1L CEP290 RTTN SSX2IP	2.16e-04	476	38	6	GO:0044782
GeneOntologyBiologicalProcess	microtubule-based movement	KIFAP3 TACR2 SPG11 CENPE AP3D1 SSX2IP	2.61e-04	493	38	6	GO:0007018
GeneOntologyBiologicalProcess	neuromuscular junction development	SPG11 FGFR2 FARP1	2.66e-04	68	38	3	GO:0007528
GeneOntologyBiologicalProcess	protein K63-linked ubiquitination	RNF8 RNF213 CEP63	3.70e-04	76	38	3	GO:0070534
GeneOntologyBiologicalProcess	otic vesicle development	FGFR2 CEP290	4.42e-04	17	38	2	GO:0071599
GeneOntologyBiologicalProcess	transport along microtubule	KIFAP3 SPG11 AP3D1 SSX2IP	4.62e-04	197	38	4	GO:0010970
GeneOntologyCellularComponent	ciliary basal body	KIFAP3 RPGRIP1L CEP290 RTTN SSX2IP	2.99e-05	195	39	5	GO:0036064
GeneOntologyCellularComponent	centrosome	KIFAP3 ACTR8 RPGRIP1L MTUS1 CEP290 RTTN SSX2IP CEP63	7.29e-05	770	39	8	GO:0005813
GeneOntologyCellularComponent	photoreceptor connecting cilium	KIFAP3 RPGRIP1L CEP290	9.80e-05	48	39	3	GO:0032391
GeneOntologyCellularComponent	microtubule organizing center	KIFAP3 ACTR8 RPGRIP1L MTUS1 CEP290 RTTN SSX2IP CEP63	2.47e-04	919	39	8	GO:0005815
GeneOntologyCellularComponent	ciliary transition zone	KIFAP3 RPGRIP1L CEP290	4.63e-04	81	39	3	GO:0035869
GeneOntologyCellularComponent	cytoplasmic region	KIFAP3 DNAL1 RPGRIP1L AP3D1 PCLO	5.24e-04	360	39	5	GO:0099568
GeneOntologyCellularComponent	excitatory synapse	AFDN FGFR2 PCLO	1.04e-03	107	39	3	GO:0060076
GeneOntologyCellularComponent	cilium	KIFAP3 TACR2 DNAL1 RPGRIP1L CEP290 RTTN SSX2IP	1.22e-03	898	39	7	GO:0005929
GeneOntologyCellularComponent	centriolar satellite	CEP290 SSX2IP CEP63	1.74e-03	128	39	3	GO:0034451
GeneOntologyCellularComponent	photoreceptor cell cilium	KIFAP3 RPGRIP1L CEP290	2.21e-03	139	39	3	GO:0097733
GeneOntologyCellularComponent	plasma membrane bounded cell projection cytoplasm	KIFAP3 DNAL1 RPGRIP1L AP3D1	2.81e-03	317	39	4	GO:0032838
GeneOntologyCellularComponent	9+0 non-motile cilium	KIFAP3 RPGRIP1L CEP290	2.90e-03	153	39	3	GO:0097731
GeneOntologyCellularComponent	microtubule	KIFAP3 DNAL1 RPGRIP1L MTUS1 CENPE	2.98e-03	533	39	5	GO:0005874
HumanPheno	Ventriculomegaly	IFIH1 RNF213 SPG11 FGFR2 DNAL1 RPGRIP1L CENPE CEP290 RTTN CEP63	1.09e-05	790	15	10	HP:0002119
HumanPheno	Lobar holoprosencephaly	RPGRIP1L CEP290 RTTN	5.16e-05	26	15	3	HP:0006870
HumanPheno	Neonatal breathing dysregulation	RPGRIP1L CEP290	8.05e-05	5	15	2	HP:0002790
HumanPheno	Aplasia/Hypoplasia of the corpus callosum	IFIH1 SPG11 FGFR2 RPGRIP1L CENPE PCLO CEP290 RTTN CEP63	8.52e-05	772	15	9	HP:0007370
MousePheno	abnormal kidney morphology	IFIH1 FSD2 AFDN FGFR2 EBNA1BP2 DNAL1 RPGRIP1L MTUS1 ZDHHC13 HIF1AN AP3D1 CEP290	5.01e-05	1363	34	12	MP:0002135
MousePheno	abnormal nephron morphology	IFIH1 FGFR2 RPGRIP1L MTUS1 ZDHHC13 AP3D1 CEP290	6.13e-05	426	34	7	MP:0003881
MousePheno	absent adenohypophysis	FGFR2 RPGRIP1L	8.56e-05	6	34	2	MP:0008320
Domain	FHA	RNF8 AFDN	1.55e-03	28	39	2	SM00240
Domain	FHA_DOMAIN	RNF8 AFDN	1.90e-03	31	39	2	PS50006
Domain	FHA	RNF8 AFDN	1.90e-03	31	39	2	PF00498
Domain	-	RNF8 SHPRH RNF213 TRIM4 PCLO	2.31e-03	449	39	5	3.30.40.10
Domain	Znf_RING/FYVE/PHD	RNF8 SHPRH RNF213 TRIM4 PCLO	2.54e-03	459	39	5	IPR013083
Domain	FHA_dom	RNF8 AFDN	2.56e-03	36	39	2	IPR000253
Domain	-	RNF8 AFDN	2.56e-03	36	39	2	2.60.200.20
Domain	C2	RPGRIP1L PCLO PLCL2	2.56e-03	131	39	3	PF00168
Domain	C2	RPGRIP1L PCLO PLCL2	2.91e-03	137	39	3	SM00239
Domain	C2	RPGRIP1L PCLO PLCL2	3.22e-03	142	39	3	PS50004
Domain	ZF_RING_2	RNF8 SHPRH RNF213 TRIM4	3.37e-03	298	39	4	PS50089
Domain	-	RPGRIP1L PCLO PLCL2	3.62e-03	148	39	3	2.60.40.150
Domain	RING	RNF8 SHPRH RNF213 TRIM4	3.66e-03	305	39	4	SM00184
Domain	Znf_RING	RNF8 SHPRH RNF213 TRIM4	4.63e-03	326	39	4	IPR001841
Domain	Znf_RING_CS	RNF8 SHPRH TRIM4	4.74e-03	163	39	3	IPR017907
Domain	C2_dom	RPGRIP1L PCLO PLCL2	4.82e-03	164	39	3	IPR000008
Domain	SMAD_FHA_domain	RNF8 AFDN	5.27e-03	52	39	2	IPR008984
Domain	ARM-type_fold	KIFAP3 URB1 AP3D1 RTTN	5.32e-03	339	39	4	IPR016024
Domain	Znf_C3HC4_RING-type	RNF8 RNF213 TRIM4	5.50e-03	172	39	3	IPR018957
Domain	P-loop_NTPase	SHPRH IFIH1 RNF213 MYH7 CENPE RAD50	7.79e-03	848	39	6	IPR027417
Domain	Butyrophylin	FSD2 TRIM4	9.38e-03	70	39	2	IPR003879
Domain	-	KIFAP3 AP3D1 RTTN	1.11e-02	222	39	3	1.25.10.10
Domain	zf-C3HC4	RNF8 RNF213 TRIM4	1.12e-02	223	39	3	PF00097
Pathway	WP_ATM_SIGNALING_IN_DEVELOPMENT_AND_DISEASE	RNF8 RAD50 CEP63	1.19e-04	47	29	3	M39518
Pathway	KEGG_MEDICUS_REFERENCE_DOUBLE_STRAND_BREAK_SIGNALING	RNF8 RAD50	3.14e-04	13	29	2	M47832
Pathway	REACTOME_NF_KB_ACTIVATION_THROUGH_FADD_RIP_1_PATHWAY_MEDIATED_BY_CASPASE_8_AND_10	IFIH1 TRIM4	3.14e-04	13	29	2	M957
Pathway	REACTOME_TRAF3_DEPENDENT_IRF_ACTIVATION_PATHWAY	IFIH1 TRIM4	4.22e-04	15	29	2	M953
Pathway	WP_JOUBERT_SYNDROME	RPGRIP1L CEP290 RAD50	4.97e-04	76	29	3	M39835
Pathway	REACTOME_CILIUM_ASSEMBLY	KIFAP3 RPGRIP1L CEP290 CEP63	7.20e-04	201	29	4	M27472
Pathway	REACTOME_ORGANELLE_BIOGENESIS_AND_MAINTENANCE	KIFAP3 RPGRIP1L CEP290 CEP63	9.59e-04	217	29	4	MM14708
Pathway	REACTOME_ANCHORING_OF_THE_BASAL_BODY_TO_THE_PLASMA_MEMBRANE	RPGRIP1L CEP290 CEP63	9.84e-04	96	29	3	MM15207
Pathway	REACTOME_ANCHORING_OF_THE_BASAL_BODY_TO_THE_PLASMA_MEMBRANE	RPGRIP1L CEP290 CEP63	1.01e-03	97	29	3	M27478
Pathway	REACTOME_TRAF6_MEDIATED_NF_KB_ACTIVATION	IFIH1 TRIM4	1.19e-03	25	29	2	M940
Pubmed	Rpgrip1l controls ciliary gating by ensuring the proper amount of Cep290 at the vertebrate transition zone.	RPGRIP1L CEP290	1.23e-06	2	39	2	33625872
Pubmed	SARS-CoV-2 Nsp8 suppresses MDA5 antiviral immune responses by impairing TRIM4-mediated K63-linked polyubiquitination.	IFIH1 TRIM4	1.23e-06	2	39	2	37956198
Pubmed	LaXp180, a mammalian ActA-binding protein, identified with the yeast two-hybrid system, co-localizes with intracellular Listeria monocytogenes.	RNF8 RB1CC1	3.67e-06	3	39	2	11207567
Pubmed	The novel centriolar satellite protein SSX2IP targets Cep290 to the ciliary transition zone.	CEP290 SSX2IP	3.67e-06	3	39	2	24356449
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	AFDN RPGRIP1L MTUS1 CENPE FARP1 CEP290 SSX2IP RAD50	3.97e-06	853	39	8	28718761
Pubmed	ADIP, a novel Afadin- and alpha-actinin-binding protein localized at cell-cell adherens junctions.	AFDN SSX2IP	7.34e-06	4	39	2	12446711
Pubmed	3D spheroid defects in NPHP knockdown cells are rescued by the somatostatin receptor agonist octreotide.	RPGRIP1L CEP290	7.34e-06	4	39	2	22832925
Pubmed	Molecular genetic analysis of 30 families with Joubert syndrome.	RPGRIP1L CEP290	7.34e-06	4	39	2	27434533
Pubmed	Exome sequencing supports a de novo mutational paradigm for schizophrenia.	KLF12 RB1CC1 PLCL2	1.25e-05	40	39	3	21822266
Pubmed	Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells.	RPGRIP1L RB1CC1 ZBTB48 TRIM4 CEP290 RAD50	1.30e-05	469	39	6	27634302
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	RNF213 RPGRIP1L RB1CC1 MTUS1 FARP1 CEP290 SSX2IP PLCL2	1.79e-05	1049	39	8	27880917
Pubmed	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.	USP25 URB1 EBNA1BP2 TRIM4 CEP290 SSX2IP RAD50	1.84e-05	754	39	7	33060197
Pubmed	The RING finger protein RNF8 ubiquitinates Nbs1 to promote DNA double-strand break repair by homologous recombination.	RNF8 RAD50	2.56e-05	7	39	2	23115235
Pubmed	A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese.	AP3D1 PLCL2	2.56e-05	7	39	2	24916648
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	RNF213 ACTR8 EBNA1BP2 TRIM4 MTUS1 ZDHHC13 SSX2IP RAD50	2.78e-05	1116	39	8	31753913
Pubmed	MRN complex-dependent recruitment of ubiquitylated BLM helicase to DSBs negatively regulates DNA repair pathways.	RNF8 RAD50	5.48e-05	10	39	2	29523790
Pubmed	Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo.	MYH7 FGFR2	5.48e-05	10	39	2	15621532
Pubmed	Role of scaffold protein afadin dilute domain-interacting protein (ADIP) in platelet-derived growth factor-induced cell movement by activating Rac protein through Vav2 protein.	AFDN SSX2IP	5.48e-05	10	39	2	22027834
Pubmed	53BP1-dependent robust localized KAP-1 phosphorylation is essential for heterochromatic DNA double-strand break repair.	RNF8 KIFAP3	6.70e-05	11	39	2	20081839
Pubmed	Docking motif-guided mapping of the interactome of protein phosphatase-1.	RPGRIP1L CENPE FARP1	1.01e-04	80	39	3	19389623
Pubmed	Proteomic and Biochemical Comparison of the Cellular Interaction Partners of Human VPS33A and VPS33B.	RPGRIP1L FARP1 SSX2IP CEP63	1.79e-04	251	39	4	29778605
Pubmed	Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy.	RPGRIP1L CEP290	1.85e-04	18	39	2	21068128
Pubmed	The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA.	SHPRH RNF213 AP3D1 RAD50	2.10e-04	262	39	4	36880596
Pubmed	FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.	SHPRH IFIH1 SPG11 CENPE AP3D1	2.25e-04	497	39	5	36774506
Pubmed	Nephronophthisis-Related Ciliopathies	RPGRIP1L CEP290	2.54e-04	21	39	2	27336129
Pubmed	Gene-environment interaction impacts on heart development and embryo survival.	MYH7 FGFR2	2.79e-04	22	39	2	30787001
Pubmed	DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation.	MYH7 CEP63	2.79e-04	22	39	2	12812986
Pubmed	Centrosomal protein Dzip1l binds Cby, promotes ciliary bud formation, and acts redundantly with Bromi to regulate ciliogenesis in the mouse.	RPGRIP1L CEP290	3.62e-04	25	39	2	29487109
Pubmed	Proteomic characterization of the human centrosome by protein correlation profiling.	CEP290 CEP63	3.91e-04	26	39	2	14654843
Pubmed	Novel asymmetrically localizing components of human centrosomes identified by complementary proteomics methods.	RPGRIP1L CEP290 CEP63	5.93e-04	146	39	3	21399614
Pubmed	An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.	KIFAP3 AFDN RPGRIP1L HIF1AN CEP290 PLCL2 RAD50	5.95e-04	1321	39	7	27173435
Pubmed	Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function.	FGFR2 CEP290	5.95e-04	32	39	2	12493773
Pubmed	Discovery and Characterization of ZUFSP/ZUP1, a Distinct Deubiquitinase Class Important for Genome Stability.	USP25 RPGRIP1L RAD50	6.05e-04	147	39	3	29576527
Pubmed	Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage.	EBNA1BP2 SSX2IP RAD50	6.29e-04	149	39	3	25184681
Pubmed	Joubert Syndrome	RPGRIP1L CEP290	6.72e-04	34	39	2	20301500
Pubmed	Gene expression profiling in the developing secondary palate in the absence of Tbx1 function.	MYH7 FGFR2	6.72e-04	34	39	2	29866044
Pubmed	Host-pathogen interactome mapping for HTLV-1 and -2 retroviruses.	SSX2IP CEP63	8.84e-04	39	39	2	22458338
Pubmed	Identifying biological pathways that underlie primordial short stature using network analysis.	AFDN URB1 EBNA1BP2 RB1CC1 CEP290 RAD50	9.13e-04	1024	39	6	24711643
Pubmed	The DNA sequence and analysis of human chromosome 13.	KLF12 PROSER1 FARP1	9.21e-04	170	39	3	15057823
Pubmed	Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?	USP25 CENPE RTTN	9.21e-04	170	39	3	23314748
Pubmed	Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism.	FSD2 KLF12 SSX2IP CEP63	1.05e-03	402	39	4	24722188
Interaction	OFD1 interactions	AFDN RPGRIP1L RB1CC1 CENPE CEP290 SSX2IP RAD50 CEP63	2.75e-07	347	39	8	int:OFD1
Interaction	CEP350 interactions	KIFAP3 RPGRIP1L HIF1AN CEP290 SSX2IP CEP63	3.94e-07	149	39	6	int:CEP350
Interaction	CEP131 interactions	AFDN RPGRIP1L CENPE CEP290 SSX2IP CEP63	2.20e-06	200	39	6	int:CEP131
Interaction	CCDC138 interactions	RPGRIP1L RB1CC1 CEP290 SSX2IP CEP63	3.81e-06	123	39	5	int:CCDC138
Interaction	NIN interactions	AFDN RPGRIP1L CENPE AP3D1 CEP290 SSX2IP CEP63	5.06e-06	359	39	7	int:NIN
Interaction	TCHP interactions	AFDN RPGRIP1L CEP290 SSX2IP CEP63	5.18e-06	131	39	5	int:TCHP
Interaction	NME7 interactions	RPGRIP1L ZBTB48 CEP290 SSX2IP CEP63	1.37e-05	160	39	5	int:NME7
Interaction	TNRC6B interactions	AFDN RPGRIP1L RB1CC1 HIF1AN SSX2IP CEP63	1.58e-05	282	39	6	int:TNRC6B
Interaction	NDC80 interactions	RPGRIP1L CENPE CEP290 SSX2IP RAD50 CEP63	2.78e-05	312	39	6	int:NDC80
Interaction	MPHOSPH9 interactions	AFDN RPGRIP1L CEP290 CEP63	3.36e-05	95	39	4	int:MPHOSPH9
Interaction	CSPP1 interactions	RPGRIP1L CEP290 SSX2IP CEP63	3.50e-05	96	39	4	int:CSPP1
Interaction	HAUS3 interactions	RPGRIP1L CEP290 SSX2IP CEP63	4.61e-05	103	39	4	int:HAUS3
Interaction	HAUS4 interactions	HIF1AN CEP290 SSX2IP CEP63	4.79e-05	104	39	4	int:HAUS4
Interaction	ANKDD1A interactions	RPGRIP1L HIF1AN	7.62e-05	7	39	2	int:ANKDD1A
Interaction	CCDC85C interactions	AFDN RPGRIP1L SSX2IP CEP63	9.81e-05	125	39	4	int:CCDC85C
Interaction	HAUS8 interactions	RPGRIP1L CEP290 SSX2IP CEP63	1.04e-04	127	39	4	int:HAUS8
Interaction	CCDC14 interactions	RNF8 CEP290 SSX2IP CEP63	1.11e-04	129	39	4	int:CCDC14
Interaction	SDC2 interactions	RNF213 FGFR2 ZBTB48 FARP1	1.65e-04	143	39	4	int:SDC2
Interaction	CEP135 interactions	RPGRIP1L CEP290 RTTN SSX2IP CEP63	1.71e-04	272	39	5	int:CEP135
Interaction	PCM1 interactions	RPGRIP1L RB1CC1 CENPE CEP290 SSX2IP CEP63	1.72e-04	434	39	6	int:PCM1
Interaction	TBC1D31 interactions	CEP290 SSX2IP CEP63	1.73e-04	56	39	3	int:TBC1D31
Interaction	SSX2IP interactions	AFDN RPGRIP1L CEP290 SSX2IP CEP63	2.23e-04	288	39	5	int:SSX2IP
Interaction	TNKS2 interactions	USP25 IFIH1 HIF1AN	2.23e-04	61	39	3	int:TNKS2
Interaction	KIAA0753 interactions	RPGRIP1L CEP290 SSX2IP CEP63	2.36e-04	157	39	4	int:KIAA0753
Interaction	SASS6 interactions	CENPE CEP290 SSX2IP CEP63	2.47e-04	159	39	4	int:SASS6
Interaction	CEP128 interactions	RPGRIP1L CEP290 SSX2IP RAD50 CEP63	2.57e-04	297	39	5	int:CEP128
Interaction	HAUS6 interactions	RPGRIP1L CEP290 SSX2IP CEP63	2.60e-04	161	39	4	int:HAUS6
Interaction	FGF3 interactions	URB1 FGFR2 EBNA1BP2	2.82e-04	66	39	3	int:FGF3
Interaction	CEP85 interactions	RNF8 RPGRIP1L SSX2IP CEP63	3.12e-04	169	39	4	int:CEP85
Interaction	ATG14 interactions	FSD2 RB1CC1 RAD50	3.21e-04	69	39	3	int:ATG14
Interaction	CEP170 interactions	KIFAP3 RPGRIP1L RB1CC1 FARP1 CEP290	3.51e-04	318	39	5	int:CEP170
Interaction	PLCH1 interactions	AFDN EBNA1BP2 HIF1AN	3.95e-04	74	39	3	int:PLCH1
Interaction	LZTS2 interactions	AFDN RPGRIP1L HIF1AN CEP290 SSX2IP CEP63	4.18e-04	512	39	6	int:LZTS2
Interaction	CCDC187 interactions	FSD2 SSX2IP CEP63	4.27e-04	76	39	3	int:CCDC187
Interaction	FGF9 interactions	AFDN FGFR2	4.30e-04	16	39	2	int:FGF9
Interaction	ENTR1 interactions	AFDN RPGRIP1L RB1CC1 SSX2IP	4.67e-04	188	39	4	int:ENTR1
Interaction	CEP43 interactions	CEP290 SSX2IP RAD50 CEP63	4.86e-04	190	39	4	int:CEP43
Interaction	SPICE1 interactions	RPGRIP1L MTUS1 SSX2IP CEP63	4.96e-04	191	39	4	int:SPICE1
Interaction	CEP192 interactions	AFDN FGFR2 RPGRIP1L CEP63	5.06e-04	192	39	4	int:CEP192
Interaction	TPGS1 interactions	AFDN CEP290 SSX2IP	5.15e-04	81	39	3	int:TPGS1
Interaction	LUZP1 interactions	RPGRIP1L CEP290 SSX2IP CEP63	5.26e-04	194	39	4	int:LUZP1
Interaction	KIAA1671 interactions	AFDN RPGRIP1L SSX2IP CEP63	5.26e-04	194	39	4	int:KIAA1671
Interaction	MST1R interactions	FGFR2 EBNA1BP2 PCLO RAD50	5.90e-04	200	39	4	int:MST1R
GeneFamily	Armadillo repeat containing\|Protein phosphatase 1 regulatory subunits	RPGRIP1L RB1CC1 CENPE FARP1	1.04e-04	181	25	4	694
GeneFamily	Ring finger proteins	RNF8 SHPRH RNF213 TRIM4	5.15e-04	275	25	4	58
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	RPGRIP1L PCLO	1.12e-03	36	25	2	823
Coexpression	HAMAI_APOPTOSIS_VIA_TRAIL_UP	USP25 IFIH1 SPG11 RB1CC1 MTUS1 CENPE CEP290 RAD50 CEP63	3.95e-07	656	39	9	M18979
Coexpression	GSE2770_TGFB_AND_IL4_ACT_VS_ACT_CD4_TCELL_6H_DN	URB1 EBNA1BP2 TRIM4 CENPE FAM76A	1.07e-05	197	39	5	M6107
ToppCell	(03)_KRT6B+-(2)_GFP_FOXI1\|(03)_KRT6B+ / shred by cell type by condition	USP25 RB1CC1 MTUS1 PCLO CEP290 RAD50	2.01e-08	199	39	6	c425e7975f492ed5cfcca022248adb627e1d27d4
ToppCell	(09)_Interm._secr.>cil.-(2)_GFP_FOXI1\|(09)_Interm._secr.>cil. / shred by cell type by condition	RB1CC1 MTUS1 AP3D1 CEP290 RAD50	8.20e-07	199	39	5	fc680f85ebd3bab4c72876a19a461b0afb5f51ce
ToppCell	(08)_Brush+PNEC-(2)_GFP_FOXI1\|(08)_Brush+PNEC / shred by cell type by condition	EBNA1BP2 RB1CC1 MTUS1 RAD50	6.41e-06	138	39	4	817e3f639604ea95adae01e8685ffaa2e0aff7a8
ToppCell	LV\|World / Chamber and Cluster_Paper	FSD2 MYH7 CHN2 PLCL2	1.83e-05	180	39	4	5ac6f485a58bb29462fec02dfbe8eb70864eafe3
ToppCell	saliva-Mild-Moderate_progression_d12-25-Epithelial-Epithelial,_Airway-secretory_cell-Epi-Secretory\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	USP25 IFIH1 MTUS1 ZDHHC13	2.12e-05	187	39	4	43ef900b76f3c38bd8ce9858201124130c743d56
ToppCell	saliva-Mild-Moderate_progression_d12-25-Epithelial-Epithelial,_Airway-secretory_cell\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	USP25 IFIH1 MTUS1 ZDHHC13	2.12e-05	187	39	4	6e5c38425b6b1d4774f8dcea7e146f1eab785c3e
ToppCell	RV-04._Ventricular_Cardiomyocyte_I\|World / Chamber and Cluster_Paper	FSD2 MYH7 CHN2 PLCL2	2.12e-05	187	39	4	78cdcf8bc141d3b155c3c8af908431fc419c4d08
ToppCell	LV-04._Ventricular_Cardiomyocyte_I\|World / Chamber and Cluster_Paper	FSD2 MYH7 CHN2 PLCL2	2.17e-05	188	39	4	0758b474457efa36488e0195f7357100f4b6a090
ToppCell	RV-06._Ventricular_Cardiomyocyte_II\|World / Chamber and Cluster_Paper	FSD2 MYH7 CHN2 PLCL2	2.21e-05	189	39	4	5e80c47f63980904c4c1ff02c201b67b456a0974
ToppCell	LV-06._Ventricular_Cardiomyocyte_II\|World / Chamber and Cluster_Paper	FSD2 MYH7 CHN2 PLCL2	2.26e-05	190	39	4	de5ef606a002f85c2e0e3a36c1f259d0b85a76ff
ToppCell	RV-06._Ventricular_Cardiomyocyte_II\|RV / Chamber and Cluster_Paper	FSD2 MYH7 CHN2 PLCL2	2.26e-05	190	39	4	fe8e78922c8ae928ef9a80bffd67868d5a87a091
ToppCell	LV-06._Ventricular_Cardiomyocyte_II\|LV / Chamber and Cluster_Paper	FSD2 MYH7 CHN2 PLCL2	2.30e-05	191	39	4	25f3eb34f4e70761e81e84c8a5829f216108cbc6
ToppCell	Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|World / Lineage, Cell type, age group and donor	AFDN FGFR2 MTUS1 FARP1	2.30e-05	191	39	4	d3733c8c4bda70c4390e5601fdda6188a64be944
ToppCell	LV-04._Ventricular_Cardiomyocyte_I\|LV / Chamber and Cluster_Paper	FSD2 MYH7 CHN2 PLCL2	2.35e-05	192	39	4	ad19e2c1d36a0566c9b12ced10db78f4781c8ea6
ToppCell	nucseq-Epithelial-Epithelial_Alveolar\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	AFDN FGFR2 MTUS1 FARP1	2.45e-05	194	39	4	53f3e49e91b1096f3226010e2de767efb490dfe4
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	AFDN FGFR2 FARP1 PCLO	2.50e-05	195	39	4	6477e6e7be5bd8eb99119a12ae16334ccddecd43
ToppCell	nucseq-Epithelial\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	AFDN FGFR2 MTUS1 FARP1	2.50e-05	195	39	4	9406866f99555198a9be311fbd65751b70f35446
ToppCell	(11)_FOXN4+-(2)_GFP_FOXI1\|(11)_FOXN4+ / shred by cell type by condition	EBNA1BP2 RB1CC1 CEP290 RAD50	2.65e-05	198	39	4	76d40b8c2f8399725b3a62ee2ae0896559cf91eb
ToppCell	(10)_Ciliated-(2)_GFP_FOXI1\|(10)_Ciliated / shred by cell type by condition	RB1CC1 AP3D1 CEP290 RAD50	2.71e-05	199	39	4	61b1ed2db71b96157b92b7535d1955a4033098da
ToppCell	(05)_Secretory-(2)_GFP_FOXI1\|(05)_Secretory / shred by cell type by condition	RB1CC1 MTUS1 AP3D1 RAD50	2.71e-05	199	39	4	d72d87e1e530ed894c0ad5e7b5b2b1d6b59fa098
ToppCell	(04)_Interm._basal>secr.-(2)_GFP_FOXI1\|(04)_Interm._basal>secr. / shred by cell type by condition	RB1CC1 MTUS1 CEP290 RAD50	2.71e-05	199	39	4	53ca3861f9e00dab3f3fbefb0837857ee39ab084
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / Treatment groups by lineage, cell group, cell type	AFDN MTUS1 FARP1 CEP290	2.76e-05	200	39	4	2dadf317a42a7e27cc1fac74f91b806c93a57108
ToppCell	NS-control\|NS / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	AFDN MTUS1 ZDHHC13 PCLO	2.76e-05	200	39	4	ecbe89ff95d046155b984c8c150e0b9e7278f839
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FGFR2 MTUS1 FARP1	2.00e-04	130	39	3	6434d9106ccb38786dad36fab80163dfc07b6eb7
ToppCell	TCGA-Mesothelium-Primary_Tumor-Mesothelioma-Epitheliod-3\|TCGA-Mesothelium / Sample_Type by Project: Shred V9	SHPRH RPGRIP1L ZDHHC13	2.33e-04	137	39	3	a1e34ebbeda3d5a4f14917282d44fcb4dcbf3133
ToppCell	facs-Lung-Endomucin-24m-Myeloid-Myeloid_Dendritic_Type_2\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SPG11 HIF1AN CEP290	2.59e-04	142	39	3	0a87c0d74e281da5dc4f59e09a5e99c62b1ea801
ToppCell	IIH-CD4-CD8_1\|IIH / Condition, Cell_class and T cell subcluster	USP25 FSD2 FGFR2	2.75e-04	145	39	3	296b6b0eea3233d76742ea35252b2f54d4c27ab6
ToppCell	Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cyth3_(Cyth3)\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	SPG11 ACTR8 SNUPN	3.22e-04	153	39	3	88ca2d2c2ab19fbee13e18951b993ee05dd30f67
ToppCell	Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cyth3_(Cyth3)-\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	SPG11 ACTR8 SNUPN	3.22e-04	153	39	3	553dff9688a1996d8f4ba16e60c683593d781389
ToppCell	droplet-Liver-Hepatocytes-18m-Myeloid-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	USP25 SNUPN PLCL2	3.41e-04	156	39	3	d72c2f5f72d269e29033f8728d924e0d4c8772c7
ToppCell	FLU-Healthy-1\|Healthy / Virus stimulation, Condition and Cluster	IFIH1 RNF213 TRIM4	3.60e-04	159	39	3	97c8e16a7ac10ebba96daee97f9fb1d4a404f23b
ToppCell	FLU-Healthy-1\|FLU / Virus stimulation, Condition and Cluster	IFIH1 RNF213 TRIM4	3.60e-04	159	39	3	fe2a9f79b058e89214256e736f6e266830cdfa28
ToppCell	saliva-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLF12 CENPE CEP290	3.67e-04	160	39	3	8e2b51d7b42e0b6e62641efdbbc73d31561d6a3e
ToppCell	367C-Lymphocytic-NK_cells-NK_cell_B2\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	CALML4 FGFR2 TRIM4	3.88e-04	163	39	3	6c4d4c55fc8a731acca13c1ba7287f238a9d81e0
ToppCell	facs-Lung-EPCAM-3m-Endothelial-vein_endothelial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DNAL1 ZBTB48 CHN2	3.95e-04	164	39	3	1d0d88132baaa3154c3e6e4ef0aff795afab08a2
ToppCell	facs-Lung-EPCAM-3m-Endothelial-Vein_endothelial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DNAL1 ZBTB48 CHN2	3.95e-04	164	39	3	bd2e10b015d5e6a338675500ec5d81dc39583b3e
ToppCell	367C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3\|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)	RPGRIP1L MTUS1 RAD50	3.95e-04	164	39	3	d2218d50e0e2d19f919dcb460b3840687c082810
ToppCell	lung-Ciliated_Epithelia\|lung / shred on tissue and cell subclass	CALML4 DNAL1 RPGRIP1L	4.16e-04	167	39	3	26cf1cfa58ee74794449a87eb19cd896e1ec8892
ToppCell	droplet-Thymus-nan-24m-Lymphocytic-double_negative_T_cell\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHPRH PROSER1 RPGRIP1L	4.23e-04	168	39	3	de1042267407719f19eb3f580a5df0c9cd0e8273
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	IFIH1 KIFAP3 SPG11	4.31e-04	169	39	3	6614c9851537e4c21b1e45ff0cc3bad07ef9d034
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	IFIH1 KIFAP3 SPG11	4.31e-04	169	39	3	665b958f4a720ca369a8a0abc7fbe8b6e13c8ce5
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D231\|Adult / Lineage, Cell type, age group and donor	FGFR2 MTUS1 FARP1	4.38e-04	170	39	3	269dee5abca9f6aa079f116f0d8f1d198604d9d4
ToppCell	367C-Lymphocytic-NK_cells-NK_cell_B2\|NK_cells / Donor, Lineage, Cell class and subclass (all cells)	CALML4 TRIM4 CHN2	4.38e-04	170	39	3	c1f7f1bb8865e954bb499963d82bb51923d5d8d6
ToppCell	368C-Myeloid-Monocyte-CD16+_Monocyte\|Monocyte / Donor, Lineage, Cell class and subclass (all cells)	SHPRH KLF12 CALML4	4.38e-04	170	39	3	4a19c7e3bb0f9c2601a10debe7000066789b4150
ToppCell	NS-critical-d_0-4-Lymphoid-B_cell\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	KLF12 URB1 RPGRIP1L	4.46e-04	171	39	3	bd1ebd9037a740ad8c01c460d778b0973d8b56df
ToppCell	3'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)-\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	RNF8 ACTR8 ZDHHC13	4.53e-04	172	39	3	5401ac7739f95fb8681cfb4747ab6e447a3c2ae8
ToppCell	3'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	RNF8 ACTR8 ZDHHC13	4.53e-04	172	39	3	b3da7f488d191214d7bb74fbac189fe8c29ee6cd
ToppCell	3'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	RNF8 ACTR8 ZDHHC13	4.53e-04	172	39	3	74dd4a7acb2cf857fed20219e4d7dc1adfbaa398
ToppCell	saliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil-Neu_c4-RSAD2\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	IFIH1 RNF213 PLCL2	4.77e-04	175	39	3	97616bb5c127284aa9e67bc336dfcf29e137164b
ToppCell	TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-1\|TCGA-Liver / Sample_Type by Project: Shred V9	DNAL1 RPGRIP1L ZDHHC13	5.01e-04	178	39	3	51c59dabf2d7aef1b1964f6f766d5ec07ef90f5a
ToppCell	FF-Differ-KC\|World / shred by cell class for mouse tongue	FSD2 CALML4 PCLO	5.09e-04	179	39	3	1526a130565a97c291a25a7a988089bffc1515c1
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	FGFR2 MTUS1 FARP1	5.09e-04	179	39	3	cb38b54261a7af5ee3347e64c8aa880a77ed0763
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	FGFR2 MTUS1 FARP1	5.09e-04	179	39	3	815b959ce8721c5ded70c0ca6e318dafc691746e
ToppCell	RV\|World / Chamber and Cluster_Paper	MYH7 CHN2 PLCL2	5.26e-04	181	39	3	bbe1e6e59d8889bd37d6e8303116cbdcafca7236
ToppCell	COVID-19-Epithelial_cells-Airway_club\|COVID-19 / group, cell type (main and fine annotations)	FGFR2 MTUS1 FARP1	5.61e-04	185	39	3	cfe6fd73d817e173fe803bc1683c291d9bcb8608
ToppCell	CV-Moderate-7\|Moderate / Virus stimulation, Condition and Cluster	SHPRH RNF213 URB1	5.61e-04	185	39	3	a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCell	CV-Moderate-7\|CV / Virus stimulation, Condition and Cluster	SHPRH RNF213 URB1	5.69e-04	186	39	3	8571956890fc9894d766ba294a28e376b4aba428
ToppCell	PND28-Epithelial-Epithelial_Airway\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CALML4 MTUS1 CEP290	5.78e-04	187	39	3	f777dd5eb5ccd554ebe1ed60a738b5dd45e18bb9
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FGFR2 MTUS1 FARP1	5.78e-04	187	39	3	58d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCell	Control-Epithelial_cells\|Control / group, cell type (main and fine annotations)	FGFR2 MTUS1 FARP1	5.87e-04	188	39	3	707ebf76cc6fb600b2f07793cf4ea9482c0de79d
ToppCell	Epithelial-Epithelial-D_(Ciliated)\|Epithelial / shred on cell class and cell subclass (v4)	CALML4 RPGRIP1L CEP290	5.87e-04	188	39	3	8f30535a32968a81a304315a49c0d90a77d36948
ToppCell	PND28-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated-Ciliated_mature\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CALML4 RPGRIP1L CEP290	5.97e-04	189	39	3	fa1ff8b7fa53f3148d9117d6e598097f03af5eb2
ToppCell	RV-04._Ventricular_Cardiomyocyte_I\|RV / Chamber and Cluster_Paper	FSD2 CHN2 PLCL2	5.97e-04	189	39	3	9c1debd65c13d63fd4f3158917d621b44b714c26
ToppCell	PND28-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CALML4 RPGRIP1L CEP290	5.97e-04	189	39	3	565063f9e3dd79164321f8a394bd12c176baf202
ToppCell	PND28-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CALML4 RPGRIP1L CEP290	5.97e-04	189	39	3	497be236848ebf5ad75d1f0c71e6261f5d3521da
ToppCell	droplet-Large_Intestine-COLON_PROXIMAL-30m-Epithelial-intestinal_crypt_stem_cell\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MTUS1 CENPE RAD50	6.06e-04	190	39	3	52c59001a079c76249abbaa3141e9e661b83d9a0
ToppCell	Children_(3_yrs)-Epithelial\|Children_(3_yrs) / Lineage, Cell type, age group and donor	FGFR2 MTUS1 FARP1	6.15e-04	191	39	3	e432c6e1ae82dddf84314ce73d2b7a991630d905
ToppCell	COVID-19-lung-AT2\|lung / Disease (COVID-19 only), tissue and cell type	FGFR2 MTUS1 PCLO	6.15e-04	191	39	3	276455a64c2c3503d5048615762eb2ee37f0ac70
ToppCell	Mild/Remission-B_activate-7\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	USP25 IFIH1 RNF213	6.15e-04	191	39	3	382686d62f7b8576c44bb9726a4e10dc26fd348e
ToppCell	(210)_NKT_cell\|World / immune cells in Peripheral Blood (logTPM normalization)	KLF12 FGFR2 FARP1	6.24e-04	192	39	3	08dc0c019c594da7b9944db8fd706aa7780e6ae9
ToppCell	Adult-Epithelial\|Adult / Lineage, Cell type, age group and donor	FGFR2 MTUS1 FARP1	6.24e-04	192	39	3	efb962a5fd3b9bdfd8cf8d13c435e29c8271713e
ToppCell	Epithelial\|World / Lineage, Cell type, age group and donor	FGFR2 MTUS1 FARP1	6.24e-04	192	39	3	499e8893afea5e6d3371e0bd018f7e86a524d669
ToppCell	(21)_NKT_cell\|World / immune cells in Peripheral Blood (logTPM normalization)	KLF12 FGFR2 FARP1	6.24e-04	192	39	3	b0a573ddde2978485a857b8261ee1ee5ef68ecef
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	AFDN FARP1 PCLO	6.34e-04	193	39	3	3866667dd221612589ae50f5c52f73a183a49ce6
ToppCell	368C-Lymphocytic-NK_cells-Proliferating_NK_cell\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	EBNA1BP2 CHN2 CENPE	6.34e-04	193	39	3	5f5904cec8b2967154ef2eab3c48f51df53aca4a
ToppCell	moderate-Myeloid-Monocyte-derived_Macrophage\|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	IFIH1 RNF213 MYH7	6.34e-04	193	39	3	22455801194bd8c73c5c397f5eac4f723429c383
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)\|390C / Donor, Lineage, Cell class and subclass (all cells)	IFIH1 KIFAP3 SPG11	6.43e-04	194	39	3	88db9f9e80c20ff3474f1f6459dcbdc25aec0b6d
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	IFIH1 KIFAP3 SPG11	6.43e-04	194	39	3	a71728202493d4858342ea2756ea281cd0d99a3a
ToppCell	Hippocampus-Neuronal\|Hippocampus / BrainAtlas - Mouse McCarroll V32	KIFAP3 RB1CC1 PCLO	6.43e-04	194	39	3	8aeb347b3024354c9505f4f0fddf0b843489dc6b
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FGFR2 FARP1 PCLO	6.43e-04	194	39	3	93c68c31e39fa44c1d05d7d4997f4f086da4e738
ToppCell	Mild/Remission-B_activate-7\|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)	USP25 IFIH1 RNF213	6.43e-04	194	39	3	01c97543972159a9468272da06e7e611e2c21fae
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	FGFR2 FARP1 PCLO	6.43e-04	194	39	3	5eaaa81f4b2535f983c424aaef00077089526a5c
ToppCell	B_cells-ISG-high_B_cells\|B_cells / Immune cells in Kidney/Urine in Lupus Nephritis	USP25 IFIH1 RNF213	6.53e-04	195	39	3	b64d9e1a8834401b4dc501566546647754ae21fc
ToppCell	Bronchial-NucSeq-Epithelial-Epi_airway_secretory-Secretory_Club\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FGFR2 MTUS1 FARP1	6.63e-04	196	39	3	ed76eeb37400ca154feae9b7ebaddb6c434f8b81
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	FGFR2 FARP1 PCLO	6.63e-04	196	39	3	6ce74aa3f0ce3ca284b67e5a4660ffd2cc9611e0
ToppCell	facs-Skin-Telogen-3m-Epithelial-bulge_keratinocyte\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	AFDN MTUS1 SSX2IP	6.63e-04	196	39	3	90edf61116ffcb4f8b6be3d0a05732d59b0a87d5
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FGFR2 FARP1 PCLO	6.63e-04	196	39	3	eea66711a16134f86e6c533a5a837ff2e0d7ca7f
ToppCell	facs-Skin-Telogen-3m-Epithelial-outer_bulge\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	AFDN MTUS1 SSX2IP	6.63e-04	196	39	3	c936014125b2ed5f796221b74acb77b8f8359875
ToppCell	COVID_non-vent-Lymphocytic-T_cell-CD8+_Memory_T_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	RNF213 KLF12 SPG11	6.73e-04	197	39	3	836061acd7f0d5de89b16f52ec679bdf09eac9db
ToppCell	mild-low-quality_cells\|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	RNF213 KLF12 RTTN	6.73e-04	197	39	3	e4331969bd911d1ebb5453f40a7057297b5389b4
ToppCell	H1299-infected-SARSCoV2\|infected / Cell line, Condition and Strain	CENPE CEP290 RAD50	6.73e-04	197	39	3	0fa3e4cf93e77d78b1f97b906c5b13ca741ae17e
ToppCell	Parenchymal-NucSeq-Epithelial-Epi_airway_secretory\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FGFR2 ZDHHC13 FARP1	6.83e-04	198	39	3	af399569c718f5fd971d73a7926768c9311002a3
ToppCell	Bronchial-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FGFR2 MTUS1 FARP1	6.93e-04	199	39	3	5f7da3eab58ace6cddb3179a415cd839d5767958
ToppCell	Neuron-Postmitotic-Excitatory_Neuron_-Parietal_and_Temporal-6\|World / Primary Cells by Cluster	KIFAP3 PCLO CEP290	6.93e-04	199	39	3	1b1bccf4293f11048709d15a3c892c0edf3da3d2
ToppCell	mild-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	RNF213 KLF12 RTTN	6.93e-04	199	39	3	f0b0097df0026496470a80d8cc9375ffd8389b00
ToppCell	Parenchymal-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FGFR2 MTUS1 FARP1	6.93e-04	199	39	3	5cea0d9e261903e0eaad60c28a07dff72ce65027
ToppCell	(02)_MMP9/10+-(2)_GFP_FOXI1\|(02)_MMP9/10+ / shred by cell type by condition	RB1CC1 CEP290 RAD50	6.93e-04	199	39	3	18a7f9ced4364f45b184bd529f32ef02c27779d3
ToppCell	Neuron-Postmitotic-Excitatory_Neuron_-Parietal_and_Temporal\|World / Primary Cells by Cluster	KIFAP3 PCLO CEP290	6.93e-04	199	39	3	4bee94c116c0da5eba951cb4cea7cc9dcdd6e30f
ToppCell	Bronchial-NucSeq-Immune_Lymphocytic-T-T_CD8-CD8_CTL\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	RNF213 KLF12 PLCL2	6.93e-04	199	39	3	eb188b0b457136b6ee485d3b3052baa30d9c0002
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Neuronal\|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type.	KIFAP3 AFDN PCLO	6.93e-04	199	39	3	77b4aa00f14b86ef5db0490be98787e063979541
Computational	Neighborhood of LCAT	MYH7 SNUPN RPGRIP1L SSX2IP	1.96e-04	133	24	4	MORF_LCAT
Drug	Carbachol [51-83-2]; Down 200; 21.8uM; MCF7; HT_HG-U133A	KIFAP3 CALML4 SNUPN RB1CC1 FARP1 CEP290	9.14e-07	194	39	6	5342_DN
Drug	Strophanthidin [66-28-4]; Down 200; 9.8uM; PC3; HT_HG-U133A	IFIH1 CALML4 SSX2IP PLCL2 CEP63	1.94e-05	194	39	5	5826_DN
Drug	Thioguanosine [85-31-4]; Down 200; 12.6uM; PC3; HT_HG-U133A	ACTR8 RB1CC1 MTUS1 HIF1AN AP3D1	1.99e-05	195	39	5	6643_DN
Drug	Parbendazole [14255-87-9]; Down 200; 16.2uM; MCF7; HT_HG-U133A	IFIH1 PCLO CEP290 SSX2IP RAD50	2.04e-05	196	39	5	3881_DN
Drug	Benzylpenicillin sodium [69-57-8]; Down 200; 11.2uM; HL60; HT_HG-U133A	ACTR8 RB1CC1 MTUS1 ZDHHC13 HIF1AN	2.04e-05	196	39	5	6155_DN
Drug	Sulfaguanidine [57-67-0]; Down 200; 18.6uM; PC3; HT_HG-U133A	KLF12 URB1 CHN2 MTUS1 PCLO	2.04e-05	196	39	5	4257_DN
Drug	Clorgyline hydrochloride [17780-75-5]; Down 200; 13uM; MCF7; HT_HG-U133A	FGFR2 SNUPN RPGRIP1L ZBTB48 CEP290	2.04e-05	196	39	5	5005_DN
Drug	Quinethazone [73-49-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A	IFIH1 AFDN KLF12 FGFR2 FAM76A	2.04e-05	196	39	5	3875_UP
Drug	Nalbuphine hydrochloride [23277-43-2]; Down 200; 10.2uM; HL60; HG-U133A	RNF8 PROSER1 ACTR8 ZBTB48 HIF1AN	2.04e-05	196	39	5	1379_DN
Drug	Oxantel pamoate [68813-55-8]; Up 200; 6.6uM; MCF7; HT_HG-U133A	IFIH1 KLF12 ACTR8 FGFR2 HIF1AN	2.04e-05	196	39	5	5338_UP
Drug	Zimelidine dihydrochloride monohydrate [61129-30-4]; Down 200; 9.8uM; HL60; HG-U133A	KIFAP3 ACTR8 ZDHHC13 HIF1AN SSX2IP	2.09e-05	197	39	5	2012_DN
Drug	Ciprofibrate [52214-84-3]; Down 200; 13.8uM; MCF7; HT_HG-U133A	ACTR8 SNUPN AP3D1 FARP1 SSX2IP	2.09e-05	197	39	5	6218_DN
Drug	Allantoin [97-59-6]; Up 200; 25.2uM; PC3; HT_HG-U133A	KLF12 PROSER1 RB1CC1 PCLO CEP290	2.09e-05	197	39	5	1800_UP
Drug	Pindolol [13523-86-9]; Down 200; 16.2uM; HL60; HG-U133A	IFIH1 KIFAP3 ZBTB48 HIF1AN AP3D1	2.09e-05	197	39	5	1392_DN
Drug	Khellin [82-02-0]; Down 200; 15.4uM; PC3; HT_HG-U133A	IFIH1 AFDN URB1 CHN2 FARP1	2.14e-05	198	39	5	6641_DN
Drug	Proglumide [6620-60-6]; Up 200; 12uM; MCF7; HT_HG-U133A	IFIH1 AFDN KLF12 URB1 FGFR2	2.14e-05	198	39	5	3972_UP
Drug	Glipizide [29094-61-9]; Down 200; 9uM; HL60; HG-U133A	KIFAP3 ACTR8 ZDHHC13 HIF1AN SSX2IP	2.14e-05	198	39	5	2008_DN
Drug	SC-58125; Down 200; 10uM; MCF7; HG-U133A	KIFAP3 FGFR2 FARP1 CEP290 SSX2IP	2.19e-05	199	39	5	254_DN
Drug	chlorpromazine hydrochloride; Down 200; 1uM; MCF7; HT_HG-U133A_EA	RNF8 URB1 ZBTB48 RAD50 CEP63	2.19e-05	199	39	5	997_DN
Drug	Tetracaone hydrochloride [136-47-0]; Down 200; 13.2uM; MCF7; HT_HG-U133A	URB1 HIF1AN CEP290 SSX2IP RAD50	2.19e-05	199	39	5	7473_DN
Drug	Gabazine [105538-73-6]; Up 200; 10.8uM; MCF7; HT_HG-U133A	IFIH1 AFDN MYH7 URB1 PCLO	2.25e-05	200	39	5	4820_UP
Drug	trifluoperazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A	CHN2 PCLO CEP290 FAM76A	2.50e-04	180	39	4	5584_UP
Drug	0175029-0000 [211245-78-2]; Down 200; 10uM; PC3; HT_HG-U133A	RNF8 ZBTB48 MTUS1 PLCL2	2.84e-04	186	39	4	6875_DN
Drug	Ethacrynic acid [58-54-8]; Up 200; 13.2uM; HL60; HG-U133A	KIFAP3 ZBTB48 HIF1AN PCLO	2.89e-04	187	39	4	1565_UP
Drug	Naftopidil dihydrochloride [57149-08-3]; Down 200; 8.6uM; HL60; HT_HG-U133A	IFIH1 CALML4 RB1CC1 SSX2IP	3.01e-04	189	39	4	2911_DN
Drug	LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A	SNUPN MTUS1 AP3D1 RAD50	3.08e-04	190	39	4	6945_DN
Drug	Harmine hydrochloride [343-27-1]; Down 200; 16uM; PC3; HT_HG-U133A	KLF12 SNUPN CENPE HIF1AN	3.08e-04	190	39	4	5855_DN
Drug	Fluvastatin sodium salt [93957-55-2]; Up 200; 9.2uM; MCF7; HT_HG-U133A	IFIH1 KIFAP3 PCLO SSX2IP	3.14e-04	191	39	4	5290_UP
Drug	Sanguinarine [2447-54-3]; Down 200; 12uM; MCF7; HT_HG-U133A	ACTR8 PCLO SSX2IP RAD50	3.14e-04	191	39	4	4168_DN
Drug	Raloxifene hydrochloride [82640-04-8]; Up 200; 7.8uM; HL60; HT_HG-U133A	AFDN FGFR2 CHN2 FARP1	3.20e-04	192	39	4	2738_UP
Drug	LY 294002; Down 200; 10uM; PC3; HT_HG-U133A	ZBTB48 FARP1 PLCL2 RAD50	3.26e-04	193	39	4	1236_DN
Drug	Diphenidol hydrochloride [3254-89-5]; Down 200; 11.6uM; MCF7; HT_HG-U133A	ACTR8 FGFR2 CEP290 RAD50	3.26e-04	193	39	4	7447_DN
Drug	Ajmalicine hydrochloride [4373-34-6]; Down 200; 10.2uM; HL60; HG-U133A	IFIH1 CALML4 ZBTB48 CENPE	3.33e-04	194	39	4	1748_DN
Drug	Thioguanosine [85-31-4]; Down 200; 12.6uM; HL60; HT_HG-U133A	IFIH1 KIFAP3 CEP290 SSX2IP	3.33e-04	194	39	4	1264_DN
Drug	Lumicolchicine gamma [6901-14-0]; Down 200; 10uM; MCF7; HT_HG-U133A	MTUS1 HIF1AN FARP1 CEP290	3.39e-04	195	39	4	3254_DN
Drug	Azaguanine-8 [134-58-7]; Down 200; 26.2uM; MCF7; HT_HG-U133A	URB1 ACTR8 FGFR2 HIF1AN	3.39e-04	195	39	4	7444_DN
Drug	Oxethazaine [126-27-2]; Up 200; 8.6uM; HL60; HG-U133A	KLF12 URB1 SSX2IP FAM76A	3.39e-04	195	39	4	1984_UP
Drug	Amiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; PC3; HT_HG-U133A	IFIH1 MYH7 FGFR2 CHN2	3.39e-04	195	39	4	4657_UP
Drug	Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; PC3; HT_HG-U133A	ACTR8 MTUS1 AP3D1 PLCL2	3.39e-04	195	39	4	4508_DN
Drug	Triamcinolone [124-94-7]; Down 200; 10.2uM; MCF7; HT_HG-U133A	URB1 FGFR2 ZBTB48 FARP1	3.39e-04	195	39	4	2241_DN
Drug	Hydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; MCF7; HT_HG-U133A	IFIH1 FGFR2 ZBTB48 CEP290	3.39e-04	195	39	4	2311_DN
Drug	Fursultiamine Hydrochloride [2105-43-3]; Down 200; 9.2uM; HL60; HT_HG-U133A	CALML4 RB1CC1 HIF1AN AP3D1	3.39e-04	195	39	4	2929_DN
Drug	AH23848 hemicalcium salt hydrate; Down 200; 1uM; MCF7; HT_HG-U133A	IFIH1 KIFAP3 FGFR2 SSX2IP	3.39e-04	195	39	4	6890_DN
Drug	0317956-0000 [391210-11-0]; Up 200; 1uM; MCF7; HT_HG-U133A	IFIH1 AFDN FGFR2 PCLO	3.39e-04	195	39	4	3969_UP
Drug	Papaverine hydrochloride [61-25-6]; Up 200; 10.6uM; PC3; HT_HG-U133A	AFDN URB1 FGFR2 FAM76A	3.46e-04	196	39	4	5769_UP
Drug	Pentetic acid [67-43-6]; Up 200; 10.2uM; PC3; HT_HG-U133A	AFDN KLF12 URB1 FGFR2	3.46e-04	196	39	4	4669_UP
Drug	Sulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; HL60; HT_HG-U133A	KLF12 HIF1AN FARP1 PCLO	3.46e-04	196	39	4	2560_UP
Drug	Mesoridazine besylate [32672-69-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	IFIH1 FARP1 CEP290 SSX2IP	3.46e-04	196	39	4	7017_DN
Drug	Conessine [546-06-5]; Up 200; 11.2uM; PC3; HT_HG-U133A	AFDN KLF12 RPGRIP1L RAD50	3.46e-04	196	39	4	4191_UP
Drug	Clemizole hydrochloride [1163-36-6]; Up 200; 11uM; HL60; HT_HG-U133A	URB1 MTUS1 AP3D1 RAD50	3.46e-04	196	39	4	2339_UP
Drug	Minaprine dihydrochloride [25953-17-7]; Up 200; 10.8uM; HL60; HG-U133A	RB1CC1 AP3D1 SSX2IP CEP63	3.46e-04	196	39	4	1968_UP
Drug	Epivincamine [6835-99-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A	FGFR2 RPGRIP1L ZBTB48 FAM76A	3.46e-04	196	39	4	2775_DN
Drug	Ribavirin [36791-04-5]; Up 200; 16.4uM; MCF7; HT_HG-U133A	KLF12 RPGRIP1L HIF1AN PCLO	3.46e-04	196	39	4	6018_UP
Drug	Tremorine dihydrochloride [300-68-5]; Up 200; 15uM; MCF7; HT_HG-U133A	AFDN RPGRIP1L ZBTB48 RAD50	3.46e-04	196	39	4	6273_UP
Drug	Molindone hydrochloride [15622-65-8]; Up 200; 12.8uM; PC3; HT_HG-U133A	KLF12 ACTR8 RPGRIP1L HIF1AN	3.53e-04	197	39	4	4199_UP
Drug	genistein; Up 200; 10uM; MCF7; HT_HG-U133A	IFIH1 ACTR8 HIF1AN SSX2IP	3.53e-04	197	39	4	6994_UP
Drug	Pivampicillin [33817-20-8]; Down 200; 8.6uM; HL60; HT_HG-U133A	ACTR8 HIF1AN SSX2IP RAD50	3.53e-04	197	39	4	2945_DN
Drug	Fluvoxamine maleate [61718-82-9]; Down 200; 9.2uM; PC3; HT_HG-U133A	CHN2 AP3D1 CEP290 RAD50	3.53e-04	197	39	4	3995_DN
Drug	Dydrogesterone [152-62-5]; Up 200; 12.8uM; HL60; HT_HG-U133A	KLF12 URB1 MTUS1 HIF1AN	3.53e-04	197	39	4	2156_UP
Drug	Gliclazide [21187-98-4]; Up 200; 12.4uM; PC3; HT_HG-U133A	AFDN URB1 FGFR2 RPGRIP1L	3.53e-04	197	39	4	5089_UP
Drug	Nisoxetine hydrochloride [57754-86-6]; Up 200; 13uM; HL60; HT_HG-U133A	KLF12 FGFR2 CHN2 FAM76A	3.53e-04	197	39	4	3117_UP
Drug	Metanephrine hydrochloride DL [881-95-8]; Up 200; 17.2uM; PC3; HG-U133A	CALML4 CEP290 PLCL2 RAD50	3.53e-04	197	39	4	1933_UP
Drug	N-Acetyl-L-leucine [1188-21-2]; Up 200; 23uM; PC3; HT_HG-U133A	RNF8 AFDN URB1 CHN2	3.53e-04	197	39	4	4622_UP
Drug	Rapamycin; Up 200; 0.1uM; HL60; HT_HG-U133A	AFDN TACR2 FGFR2 MTUS1	3.53e-04	197	39	4	6180_UP
Drug	Pralidoxime chloride [51-15-0]; Up 200; 23.2uM; MCF7; HT_HG-U133A	IFIH1 KLF12 CHN2 PCLO	3.53e-04	197	39	4	5383_UP
Drug	DAPH; Down 200; 10uM; MCF7; HG-U133A	CALML4 MTUS1 HIF1AN SSX2IP	3.53e-04	197	39	4	624_DN
Drug	Articaine hydrochloride [23964-57-0]; Up 200; 12.4uM; HL60; HT_HG-U133A	KLF12 FGFR2 MTUS1 HIF1AN	3.53e-04	197	39	4	3138_UP
Drug	Bumetanide [28395-03-1]; Up 200; 11uM; MCF7; HT_HG-U133A	KIFAP3 CEP290 SSX2IP CEP63	3.53e-04	197	39	4	7440_UP
Drug	Bethanechol chloride [590-63-6]; Up 200; 20.4uM; PC3; HT_HG-U133A	AFDN URB1 CHN2 CEP290	3.60e-04	198	39	4	5114_UP
Drug	Suramin sodium salt; Up 200; 10uM; MCF7; HT_HG-U133A	RNF8 PCLO CEP290 SSX2IP	3.60e-04	198	39	4	7524_UP
Drug	Tiletamine hydrochloride; Up 200; 15.4uM; MCF7; HT_HG-U133A	IFIH1 AFDN CHN2 PCLO	3.60e-04	198	39	4	6013_UP
Drug	Ceftazidime pentahydrate [78439-06-2]; Down 200; 6.2uM; HL60; HG-U133A	RNF8 IFIH1 ZBTB48 SSX2IP	3.60e-04	198	39	4	1721_DN
Drug	Mianserine hydrochloride [21535-47-7]; Down 200; 13.2uM; PC3; HT_HG-U133A	ACTR8 ZBTB48 HIF1AN CEP290	3.60e-04	198	39	4	2068_DN
Drug	Lycorine hydrochloride [2188-68-3]; Up 200; 12.4uM; MCF7; HT_HG-U133A	IFIH1 AFDN KLF12 FAM76A	3.60e-04	198	39	4	3891_UP
Drug	Acetohexamide [968-81-0]; Down 200; 12.4uM; MCF7; HT_HG-U133A	ACTR8 FARP1 SSX2IP RAD50	3.60e-04	198	39	4	7482_DN
Drug	Xylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; PC3; HT_HG-U133A	KLF12 ACTR8 CALML4 CEP63	3.60e-04	198	39	4	2107_DN
Drug	Urosiol [128-13-2]; Up 200; 10.2uM; PC3; HT_HG-U133A	FGFR2 CHN2 MTUS1 RAD50	3.60e-04	198	39	4	7243_UP
Drug	Felbinac [5728-52-9]; Down 200; 18.8uM; MCF7; HT_HG-U133A	URB1 FGFR2 HIF1AN FARP1	3.60e-04	198	39	4	3398_DN
Drug	celecoxib; Down 200; 10uM; MCF7; HG-U133A	KIFAP3 TACR2 FGFR2 FARP1	3.60e-04	198	39	4	252_DN
Drug	WY-14643; Down 200; 100uM; PC3; HG-U133A	KIFAP3 MYH7 URB1 MTUS1	3.60e-04	198	39	4	481_DN
Drug	Glafenine hydrochloride [65513-72-6]; Up 200; 9.8uM; HL60; HT_HG-U133A	RPGRIP1L CHN2 MTUS1 SSX2IP	3.60e-04	198	39	4	2387_UP
Drug	Captopril [62571-86-2]; Up 200; 17.2uM; PC3; HG-U133A	KIFAP3 KLF12 SSX2IP RAD50	3.60e-04	198	39	4	1907_UP
Drug	Guaifenesin [93-14-1]; Up 200; 20.2uM; PC3; HT_HG-U133A	AFDN URB1 FGFR2 FAM76A	3.60e-04	198	39	4	3814_UP
Drug	Netilmicin sulfate [56931-57-2]; Down 200; 2.8uM; PC3; HT_HG-U133A	ACTR8 CALML4 CHN2 HIF1AN	3.60e-04	198	39	4	7302_DN
Drug	Pirlindole mesylate [60762-57-4]; Up 200; 12.4uM; HL60; HT_HG-U133A	AFDN CHN2 HIF1AN FAM76A	3.60e-04	198	39	4	3140_UP
Drug	2-propylpentanoic acid; Up 200; 1000uM; HL60; HT_HG-U133A	URB1 FGFR2 RPGRIP1L PLCL2	3.60e-04	198	39	4	6168_UP
Drug	Chlorogenic acid [327-97-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A	KLF12 URB1 CHN2 HIF1AN	3.60e-04	198	39	4	4142_UP
Drug	nitrendipine; Down 200; 10uM; MCF7; HG-U133A	ZBTB48 AP3D1 CEP290 CEP63	3.60e-04	198	39	4	336_DN
Drug	Gliquidone [33342-05-1]; Up 200; 7.6uM; MCF7; HT_HG-U133A	URB1 CHN2 PLCL2 FAM76A	3.67e-04	199	39	4	6505_UP
Drug	Nifenazone [2139-47-1]; Down 200; 13uM; HL60; HG-U133A	ZBTB48 HIF1AN AP3D1 PLCL2	3.67e-04	199	39	4	1439_DN
Drug	Cyclacillin [3485-14-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	AFDN KLF12 FGFR2 PLCL2	3.67e-04	199	39	4	3882_UP
Drug	Hexetidine [141-94-6]; Down 200; 11.8uM; PC3; HT_HG-U133A	KLF12 CHN2 MTUS1 FARP1	3.67e-04	199	39	4	6319_DN
Drug	Testosterone propionate [57-85-2]; Up 200; 11.6uM; HL60; HT_HG-U133A	CHN2 MTUS1 HIF1AN CEP290	3.67e-04	199	39	4	1295_UP
Drug	Yohimbine hydrochloride [65-19-0]; Down 200; 10.2uM; HL60; HG-U133A	KIFAP3 ACTR8 CALML4 CEP63	3.67e-04	199	39	4	1763_DN
Drug	Trimethylcolchicinic acid [3482-37-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A	FGFR2 AP3D1 FARP1 RAD50	3.67e-04	199	39	4	2802_DN
Drug	Bupropion hydrochloride [31677-93-7]; Up 200; 14.4uM; MCF7; HT_HG-U133A	ZBTB48 HIF1AN AP3D1 PCLO	3.67e-04	199	39	4	6256_UP
Drug	(+/-)-blebbistatin; Down 200; 17uM; MCF7; HT_HG-U133A_EA	ACTR8 FGFR2 MTUS1 HIF1AN	3.67e-04	199	39	4	954_DN
Drug	Mebhydroline 1,5-naphtalenedisulfonate [6153-33-9]; Down 200; 4.8uM; MCF7; HT_HG-U133A	FGFR2 MTUS1 SSX2IP CEP63	3.67e-04	199	39	4	4795_DN
Drug	Dihydroergocristine mesylate [24730-10-7]; Up 200; 5.6uM; PC3; HT_HG-U133A	IFIH1 RPGRIP1L CHN2 RAD50	3.67e-04	199	39	4	7275_UP
Drug	tetraethylenepentamine pentahydrochloride; Down 200; 100uM; ssMCF7; HG-U133A	KIFAP3 CALML4 MTUS1 CENPE	3.67e-04	199	39	4	498_DN
Disease	Meckel-Gruber syndrome	RPGRIP1L CEP290	7.22e-05	10	38	2	cv:C0265215
Disease	leptin measurement	FGFR2 RB1CC1 CHN2	1.57e-04	81	38	3	EFO_0005000
Disease	Meckel-Gruber syndrome	RPGRIP1L CEP290	1.68e-04	15	38	2	C0265215
Disease	Meckel syndrome type 1	RPGRIP1L CEP290	2.44e-04	18	38	2	C3714506
Disease	Familial aplasia of the vermis	RPGRIP1L CEP290	3.02e-04	20	38	2	cv:C0431399
Disease	Primary microcephaly	RTTN CEP63	3.67e-04	22	38	2	C0431350
Disease	Polydactyly	FGFR2 RPGRIP1L CEP290	4.63e-04	117	38	3	C0152427
Disease	ciliopathy (implicated_via_orthology)	RPGRIP1L CEP290	1.22e-03	40	38	2	DOID:0060340 (implicated_via_orthology)
Disease	lipoprotein-associated phospholipase A(2) measurement	RNF213 SSX2IP	1.22e-03	40	38	2	EFO_0004746

Protein segments in the cluster

Peptide	Gene	Start	Entry
KEKLEKQQQMHIVDM	AFDN	1521	P55196
MHMQIKQEDPKKEIL	CALML4	116	Q96GE6
LMENAELKKVLQQMK	SSX2IP	271	Q9Y2D8
NKQHVKELVNMILMK	ACTR8	241	Q9H981
KNLMEIVKKLMTHVD	AP3D1	371	O14617
HLKEMGQMQVLQMKS	RAD50	1041	Q92878
RMKKNMEQTIKDLQH	MYH7	1781	P12883
MIMLQNHRKLLDIKQ	RB1CC1	421	Q8TDY2
EMMKMIGKHKNIINL	FGFR2	536	P21802
KTRNMLIMQHKINKD	RPGRIP1L	511	Q68CZ1
KAHQKVAIMRNIEKM	HIF1AN	311	Q9NWT6
NEKLHQQDIKLMKME	MTUS1	1151	Q9ULD2
QKRQQEKAHMMNAIK	EBNA1BP2	186	Q99848
IMVQKKLEELQSMKQ	PCLO	3251	Q9Y6V0
QLKAMKALQHKMVAV	PROSER1	51	Q86XN7
LMIHLKKVTMNEKDN	CHN2	406	P52757
IQLQNDKLKIMQEMK	CEP290	1291	O15078
MIKMENFQKLHELKK	FARP1	731	Q9Y4F1
QELMKQIDIMVAHKK	CEP63	26	Q96MT8
HKILELQMQSIMEKK	IFIH1	871	Q9BYX4
MNIHMKRKTIKNINT	KLF12	1	Q9Y4X4
IHIMKKLKILYMSNN	DNAL1	111	Q4LDG9
MSHKKINEMEQLKKQ	CENPE	1991	Q02224
HLQAMKKFVKTMVLV	TACR2	241	P21452
ELKMRNKNIVHMLVK	KIFAP3	296	Q92845
AVIMQDIKMHAVVKK	RTTN	856	Q86VV8
IQMQEKHEAVMNVKK	RNF8	261	O76064
IHKNMYKLEKQIIEM	FSD2	216	A1L4K1
KQQKVMVQHMKKLLG	PLCL2	526	Q9UPR0
KFNQLMKKVMEKLHN	SHPRH	236	Q149N8
LQQIMEHKKSQKEGM	SNUPN	306	O95149
ATLKKMLHQKDQMIL	FAM76A	226	Q8TAV0
TNIVKKLMNNHMKLI	URB1	121	O60287
KQHQPTDMVMENLKK	SPG11	2386	Q96JI7
HDKMKMQLNVKNVPL	RNF213	2006	Q63HN8
QFMQKKDLQSHMIKL	ZBTB48	386	P10074
MALQNKNQLIIHMLK	ZDHHC13	256	Q8IUH4
KNQLIIHMLKTEAKM	ZDHHC13	261	Q8IUH4
HNIMKVAQAKLEMIK	USP25	841	Q9UHP3
NLVAKMKKVMHLQDV	TRIM4	166	Q9C037
MKKVMHLQDVEVKNA	TRIM4	171	Q9C037